source name	characteristics[organism]	characteristics[organism part]	characteristics[cell type]	characteristics[cell line]	characteristics[developmental stage]	characteristics[disease]	characteristics[ancestry category]	characteristics[sex]	characteristics[age]	characteristics[biological replicate]	characteristics[time]	characteristics[treatment]	characteristics[individual]	Material Type	technology type	assay name	comment[data file]	comment[file uri]	comment[technical replicate]	comment[fraction identifier]	comment[label]	comment[instrument]	comment[modification parameters]	comment[modification parameters]	comment[cleavage agent details]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	factor value[treatment]
PXD021865-Sample-1	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	pertuzumab	111	tissue	proteomic profiling by mass spectrometer	run 8	20151118_HER2_09.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_09.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-1	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	pertuzumab	111	tissue	proteomic profiling by mass spectrometer	run 29	20151123_HER2_10rerun.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151123_HER2_10rerun.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-2	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	2	Pre	pertuzumab	116	tissue	proteomic profiling by mass spectrometer	run 17	20151121_HER2_17.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_17.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-2	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	2	Post	pertuzumab	116	tissue	proteomic profiling by mass spectrometer	run 18	20151121_HER2_18.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_18.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-3	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	3	Pre	pertuzumab	118	tissue	proteomic profiling by mass spectrometer	run 21	20151122_HER2_21.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_21.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-3	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	3	Post	pertuzumab	118	tissue	proteomic profiling by mass spectrometer	run 22	20151122_HER2_22.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_22.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-4	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	4	Post	pertuzumab	128	tissue	proteomic profiling by mass spectrometer	run 38	20170113_Johnson_128-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_128-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-4	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	4	Pre	pertuzumab	128	tissue	proteomic profiling by mass spectrometer	run 39	20170113_Johnson_128-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_128-R.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	pertuzumab
PXD021865-Sample-5	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	5	Pre	trastuzumab	103	tissue	proteomic profiling by mass spectrometer	run 3	20151118_HER2_03.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_03.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-5	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	5	Post	trastuzumab	103	tissue	proteomic profiling by mass spectrometer	run 4	20151118_HER2_04.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_04.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-6	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	6	Post	trastuzumab	108	tissue	proteomic profiling by mass spectrometer	run 32	20170113_Johnson_108-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_108-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-6	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	6	Pre	trastuzumab	108	tissue	proteomic profiling by mass spectrometer	run 33	20170113_Johnson_108-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_108-R.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-7	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	7	Pre	trastuzumab	113	tissue	proteomic profiling by mass spectrometer	run 13	20151120_HER2_13.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151120_HER2_13.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-7	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	7	Post	trastuzumab	113	tissue	proteomic profiling by mass spectrometer	run 14	20151120_HER2_30.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151120_HER2_30.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-8	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	8	Post	trastuzumab	123	tissue	proteomic profiling by mass spectrometer	run 34	20170113_Johnson_123-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_123-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-8	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	8	Pre	trastuzumab	123	tissue	proteomic profiling by mass spectrometer	run 35	20170113_Johnson_123-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_123-R.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab
PXD021865-Sample-9	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+lapatinib	107	tissue	proteomic profiling by mass spectrometer	run 5	20151118_HER2_06.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_06.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+lapatinib
PXD021865-Sample-9	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+lapatinib	107	tissue	proteomic profiling by mass spectrometer	run 10	20151118_HER2_29.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_29.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+lapatinib
PXD021865-Sample-10	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	2	Pre	trastuzumab+lapatinib	121	tissue	proteomic profiling by mass spectrometer	run 27	20151122_HER2_27.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_27.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+lapatinib
PXD021865-Sample-10	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	2	Post	trastuzumab+lapatinib	121	tissue	proteomic profiling by mass spectrometer	run 28	20151122_HER2_28.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_28.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+lapatinib
PXD021865-Sample-11	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	3	Post	trastuzumab+lapatinib	125	tissue	proteomic profiling by mass spectrometer	run 36	20170113_Johnson_125-O.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_125-O.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+lapatinib
PXD021865-Sample-11	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	3	Pre	trastuzumab+lapatinib	125	tissue	proteomic profiling by mass spectrometer	run 37	20170113_Johnson_125-R.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20170113_Johnson_125-R.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+lapatinib
PXD021865-Sample-12	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Pre	trastuzumab+pertuzumab	101	tissue	proteomic profiling by mass spectrometer	run 1	20151118_HER2_01.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_01.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-12	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	1	Post	trastuzumab+pertuzumab	101	tissue	proteomic profiling by mass spectrometer	run 2	20151118_HER2_02.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_02.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-13	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	2	Pre	trastuzumab+pertuzumab	109	tissue	proteomic profiling by mass spectrometer	run 6	20151118_HER2_07.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_07.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-13	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	2	Post	trastuzumab+pertuzumab	109	tissue	proteomic profiling by mass spectrometer	run 7	20151118_HER2_08.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151118_HER2_08.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-14	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	3	Pre	trastuzumab+pertuzumab	115	tissue	proteomic profiling by mass spectrometer	run 15	20151121_HER2_15.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_15.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-14	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	3	Post	trastuzumab+pertuzumab	115	tissue	proteomic profiling by mass spectrometer	run 16	20151121_HER2_16.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151121_HER2_16.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-15	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	4	Pre	trastuzumab+pertuzumab	119	tissue	proteomic profiling by mass spectrometer	run 23	20151122_HER2_23.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_23.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-15	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	4	Post	trastuzumab+pertuzumab	119	tissue	proteomic profiling by mass spectrometer	run 24	20151122_HER2_24.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_24.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-16	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	5	Pre	trastuzumab+pertuzumab	120	tissue	proteomic profiling by mass spectrometer	run 25	20151122_HER2_25.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_25.raw	1	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab
PXD021865-Sample-16	Homo sapiens	breast	not applicable	not applicable	not applicable	HER2+ breast cancer	not available	female	not available	5	Post	trastuzumab+pertuzumab	120	tissue	proteomic profiling by mass spectrometer	run 26	20151122_HER2_26.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/04/PXD021865/20151122_HER2_26.raw	2	1	AC=MS:1002038;NT=label free sample	NT=Q Exactive HF;AC=MS:1002523	NT=Carbamidomethyl;TA=C;AC=UNIMOD:4;MT=fixed	"NT=Phospho;AC=UNIMOD:21;TA=S,T,Y;MT=Variable"	NT=Trypsin; AC=MS:1001251	20 ppm	4.5 ppm	trastuzumab+pertuzumab